Drug Trial Radar · NCT04497116
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
276
Actual
Start
Jul 22, 2020
Primary completion
Jun 13, 2025
Study completion Jun 13, 2025
Sponsor
- Lead sponsor
- Repare TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to define the maximum tolerated dose (MTD) and determine a recommended Phase 2 dose (RP2D) and schedule of orally-administered RP-3500 (camonsertib) alone or in combination with talazoparib, a PARP inhibitor, or Gemcitabine in patients with advanced solid tumors with ATR inhibitor-sensitizing mutations. This study will also evaluate the safety and tolerability of RP-3500 (camonsertib) alone or in combination with talazoparib or gemcitabine, examine both the pharmacokinetics (PK)and pharmacodynamics (PD)and investigate its anti-tumor activity in solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
RP-3500 (camonsertib)Drug
Oral ATR inhibitor
TalazoparibDrug
Oral PARP inhibitor
Gemcitabine InjectionDrug
Gemcitabine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and AboveTime frame: Start of treatment to 30 days post last dose, up to 1 year
- Frequency of Dose Limiting Toxicity (DLT)Time frame: Either 21 days or 28 days (1 cycle) from the initiation of the study treatment.
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
#1014, Northwestern University
Chicago, Illinois
#1006, Massachusetts General Hospital
Boston, Massachusetts
#1002, Dana Farber Cancer Institute
Boston, Massachusetts
#1004, Memorial Sloan Kettering Cancer Institute
New York, New York
#1005, Duke Cancer Institute
Durham, North Carolina
#1007, Rhode Island Hospital
Providence, Rhode Island
#1003, Sarah Cannon Research Institute
Nashville, Tennessee
#1001, The University of Texas M.D. Anderson Cancer Center
Houston, Texas
#2001, Princess Margaret Cancer Centre
Toronto, Ontario, Canada
#4001, Copenhagen University Hospital Rigshospitalet - Blegdamsvej
Copenhagen, DK, Denmark
#3003, Sarah Cannon Research Institute
London, United Kingdom
#3001, The Christie NHS Foundation Trust
Manchester, United Kingdom
#3002, Freeman Hospital Newcastle
Newcastle upon Tyne, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.